Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: Exploring the Role of Genotype-Guided Therapy in Reducing Readmission Rates
- PMID: 37500316
- DOI: 10.1016/j.amjcard.2023.07.043
Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: Exploring the Role of Genotype-Guided Therapy in Reducing Readmission Rates
Comment on
-
Rates of 30-Day and 90-Day Readmission Between Genotype-Optimal and Genotype-Suboptimal Antiplatelet Therapy Prescribing After Percutaneous Coronary Intervention.Am J Cardiol. 2023 Sep 1;202:218-222. doi: 10.1016/j.amjcard.2023.06.090. Epub 2023 Jul 18. Am J Cardiol. 2023. PMID: 37473671
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
